Comparison of the 3/5000 effectiveness, safety and brain protection of remazolam tosylate and midazolam in patients with moderate craniocerebral injury

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048602

Enrollment

Unknown

Registered

2021-07-11

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic brain injury

Interventions

Group 1:remazolam tosylate

Group 2:midazolam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Admission to the hospital within 6 hours after injury; CT examination confirmed craniocerebral injury patients; GCS score 9-12; more than 18 years of age; It was estimated that > 2 days after ICU hospitalization; The presence of restlessness and other psychiatric symptoms.

Exclusion criteria

Exclusion criteria: In addition to craniocerebral injury, combined with other serious organ damage or severe heart, liver, kidney and other vital organ dysfunction; patients with contraindications to benzodiazepines/propofol/opioids; previous brain damage or severe certification Patients with disabilities; patients who died or voluntarily gave up treatment during treatment; patients with disease progression requiring surgery.

Design outcomes

Primary

Measure	Time frame
Sedative dose;regional cerebral oxygen saturation;Internal jugular vein oxygen saturation;Cerebral oxygen uptake;	—

Countries

China

Contacts

Public ContactLan Chao

The First Affiliated Hospital of Zhengzhou University

lanchao29@163.com+86 13663855629

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026